Table 1 Model-based risk stratification for cortical LBP (LBPctx) positivity

From: Two-step detection of Lewy body pathology via smell-function testing and CSF α-synuclein seed amplification

 

Whole cohort

Clinical parkinsonism

Clinical AD

Clinically unimpaired

 

All

LBPctx-

LBPctx+

All

LBPctx-

LBPctx+

All

LBPctx-

LBPctx+

All

LBPctx-

LBPctx+

80% sensitivity

Low risk

213

190 (89.2)

23 (10.8)

57

47 (82.5)

10 (17.5)

54

49 (89.3)

5 (10.7)

42

38 (90.5)

4 (9.5)

High risk

143

41 (28.7)

102 (71.3)

93

9 (9.7)

84 (90.3)

41

22 (53.7)

21 (46.3)

2

1 (50.0)

1 (50.0)

85% sensitivity

Low risk

203

183 (90.1)

20 (9.9)

52

44 (84.6)

8 (15.4)

49

45 (91.8)

4 (8.2)

42

38 (90.5)

4 (9.5)

High risk

157

49 (31.2)

106 (68.8)

98

12 (12.2)

86 (87.8)

48

26 (54.2)

22 (45.8)

2

1 (50.0)

1 (50.0)

90% sensitivity

Low risk

187

173 (92.5)

14 (7.5)

47

43 (91.5)

4 (7.0)

45

43 (95.6)

2 (4.4)

39

35 (89.7)

4 (10.3)

High risk

171

59 (34.5)

112 (65.5)

103

13 (12.6)

90 (87.4)

52

28 (53.8)

24 (46.2)

5

4 (80.0)

1 (20.0)

95% sensitivity

Low risk

154

148 (96.1)

6 (3.9)

35

34 (97.1)

1 (2.9)

33

32 (97.0)

1 (3.0)

35

33 (94.3)

2 (5.7)

High risk

214

84 (39.3)

120 (60.7)

115

22 (19.1)

93 (80.9)

64

39 (60.9)

25 (38.1)

9

6 (66.7)

3 (33.3)

  1. Data are presented as n or n (%). The first column indicates the evaluated strategies with different sensitivity-based thresholds for UPSIT-derived risk stratification. For each strategy, the total number of individuals in the low- and high-risk groups are shown, followed by numbers of Lewy body pathology negative (LBP-) and LBP+ participants according to postmortem cortical neuropathology measures (ctx). The percentage of LBPctx-negatives in the low-risk group and the percentage of LBPctx-positives in the high-risk group correspond to each evaluated threshold’s NPV and PPV, respectively.
  2. AD Alzheimer’s disease, ctx cortex, LBP Lewy body pathology.
Back to article page